64 results
424B5
TCRX
Tscan Therapeutics Inc
17 Apr 24
Prospectus supplement for primary offering
9:58pm
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about … the audit and the financial statements;
S-3
not being required to disclose certain executive compensation-related items such as the correlation between
424B5
ig82j2x
16 Apr 24
Prospectus supplement for primary offering
5:21pm
8-K
ixe8a9m0dm jq
29 Jan 24
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
7:15am
8-K
our44jhm
7 Dec 23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7:15am